CytomX (CTMX) director Elaine Jones awarded 59,000 stock options at $2.96 strike

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. reported that director Elaine V. Jones received a stock option grant. She was awarded options to acquire 59,000 shares of common stock at an exercise price of $2.96 per share, giving her rights to buy shares at that price in the future.

After this grant, she holds 59,000 derivative securities linked to common stock. According to the terms, all 59,000 option shares will vest in full on the earlier of the first anniversary of the grant date or the date of the 2027 annual stockholder meeting, assuming she continues serving as a director until that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jones Elaine V

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	59,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 59,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 59,000 options Exercise price: $2.96 per share Underlying shares: 59,000 shares +1 more

4 metrics

Options granted 59,000 options Stock Option (Right to Buy) grant to director

Exercise price $2.96 per share Conversion or exercise price of options

Underlying shares 59,000 shares Common stock underlying the stock options

Option expiration June 16, 2036 Expiration date of stock option grant

Key Terms

Stock Option (Right to Buy), exercise price, vest in full, Annual Meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"100% of the shares subject to the option shall vest in full"

Annual Meeting of the Issuer's stockholders regulatory

"the date of the 2027 Annual Meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:46 PM Accepted by SEC EDGAR 06/22/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Elaine V

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/17/2026		A		59,000		(1)	06/16/2036	Common Stock	59,000	$0	59,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Elaine V. Jones	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CytomX Therapeutics (CTMX) disclose in this Form 4?

CytomX disclosed a stock option grant to director Elaine V. Jones. She received options for 59,000 shares of common stock at an exercise price of $2.96 per share, increasing her equity-linked compensation position.

How many CytomX (CTMX) options did Elaine V. Jones receive?

Elaine V. Jones received a grant of 59,000 stock options. Each option is exercisable into one share of CytomX common stock, giving her potential future ownership of up to 59,000 shares if she chooses to exercise.

What is the exercise price of the new CTMX stock options?

The new stock options for Elaine V. Jones have an exercise price of $2.96 per share. This is the fixed price at which she can buy CytomX common shares once the options vest and are exercised.

When do Elaine V. Jones’s CTMX options vest?

All 59,000 options will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual meeting. Vesting is conditioned on her continuous service as a director until that vesting date.

Is this CTMX Form 4 an open-market purchase or sale?

No, this Form 4 reflects a grant/award acquisition of stock options, not an open-market trade. The options were granted as compensation, so no buy or sell transaction occurred in the market.